A single agent trial of FLX 787 for treatment of cramps associated with amyotrophic lateral sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis; Cramp
- Focus Therapeutic Use
- Sponsors Flex Pharma
- 06 Nov 2017 According to a Flex Pharma media release, the study was terminated early to focus the Companys resources on the ongoing US Phase 2b ALS study (COMMEND).
- 06 Nov 2017 Results (n=8) presented in a Flex Pharma media release.
- 02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.